Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹19,800 Cr
Revenue (TTM)
₹3,151 Cr
Net Profit (TTM)
₹22 Cr
ROE
-1.5 %
ROCE
4.1 %
P/E Ratio
900
P/B Ratio
4.3
Industry P/E
46.99
EV/EBITDA
38.3
Div. Yield
0 %
Debt to Equity
0.4
Book Value
₹284.8
EPS
₹6.8
Face value
5
Shares outstanding
162,492,169
CFO
₹1,178.86 Cr
EBITDA
₹1,278.89 Cr
Net Profit
₹-2,817.04 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Wockhardt
| -15.9 | -12.9 | -10.5 | -5.8 | 92.6 | 23.6 | 3.3 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Wockhardt
| -0.7 | 201.6 | 90.2 | -41.2 | -24.1 | 132.6 | -55.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Wockhardt
|
1,215.6 | 19,800.5 | 3,151.0 | -10.0 | 8.4 | 2.5 | 900 | 4.3 |
| 2,257.8 | 18,500.8 | 1,215.1 | 284.8 | 28.7 | 21.1 | 64.5 | 12.2 | |
| 676.3 | 13,282.8 | 7,266.8 | 627.5 | 11.9 | 12.6 | 21.1 | 2.4 | |
| 306.3 | 11,719.9 | 2,051.5 | 180.5 | 11.6 | 7.7 | 58.1 | 3.1 | |
| 587.2 | 14,551.9 | 5,092.5 | 545.5 | 15.9 | 14.1 | 26.7 | 3.5 | |
| 856.6 | 13,645.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 31.5 | 2.1 | |
| 957.9 | 17,149.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11 | 2.0 | |
| 1,471.6 | 16,867.1 | 1,419.3 | 20.1 | 8.4 | 0.5 | 839.1 | 2.9 | |
| 143.1 | 19,028.2 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 419.9 | 16,903.3 | 3,720.2 | 352.1 | 13.7 | 8.2 | 48 | 3.6 |
5 min read•By Research Desk
3 min read•By Research Desk
2 min read•By Research Desk
4 min read•By Research Desk
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It... develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company's biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine. Its pipeline also includes rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. In addition, the company provides contract manufacturing services. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India. Read more
Incorporated
1999
Chairman
Habil Khorakiwala
Managing Director
Murtaza Khorakiwala
Group
Wockhardt
Headquarters
Chhatrapati Sambhajinagar - (Aurangabad), Maharashtra
Website
Looking for more details about Wockhardt Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Wockhardt Ltd is ₹1,215.60 (NSE) and ₹1,218.55 (BSE) as of 18-Mar-2026 IST. Wockhardt Ltd has given a return of 92.6% in the last 3 years.
The P/E ratio of Wockhardt Ltd is 900.02 times as on 18-Mar-2026, a 1815 premium to its peers’ median range of 46.99 times.
The P/B ratio of Wockhardt Ltd is 4.28 times as on 18-Mar-2026, a 42 premium to its peers’ median range of 3.02 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
5.31
|
|
2024
|
0.00
|
2.69
|
|
2023
|
0.00
|
0.66
|
|
2022
|
0.00
|
0.99
|
|
2021
|
6.12
|
1.36
|
The 52-week high and low of Wockhardt Ltd are Rs 1,868.80 and Rs 1,154.40 as of 19-Mar-2026.
Wockhardt Ltd has a market capitalisation of ₹ 19,800 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Wockhardt Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹26.90
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.